Other studies also support that the extent of microglial suppression with the CSF1R inhibitor is consistent when given under physiological conditions but highly variable in neurological disorders including AD, Parkinson's disease, ischemia, and epilepsy (13, 19, 25, 43) which suggest that the activation of CSF1R signaling or the levels of CSF1 may be differently altered under variable pathological conditions, including during the period of epileptogenesis. This evidence concerns the gene CSF1 and nervous system disorder.